Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 0.45 |
| ▸ | BRD2 | P25440 | 2/20 | 0.45 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CCL2 | P13500 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17854803 | 0.73 | BRD4 (0.61) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL19308921 | 0.73 | BRD4 (0.72) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL17854808 | 0.71 | USP1 (0.41) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL17854807 | 0.71 | BRD4 (0.72) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL17854804 | 0.69 | BRD4 (0.47) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL19566585 | 0.65 | BRD4 (0.52) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL18249957 | 0.64 | BRD4 (0.78) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL21142457 | 0.64 | BRD4 (0.55) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL12098880 | 0.63 | BRD4 (0.59) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL17581422 | 0.63 | BRD4 (0.49) | BRD4BRD2BRD3CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | BRD4 687/4885BRD2 529/4885BRD3 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.